Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 studyKohei Shitara, Yung‐Jue Bang, Nina Karaseva et al.|The Lancet Oncology|2023Cited by 336
Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial CancerJacqueline Vuky, Elizabeth R. Plimack, Arjun Vasant Balar et al.|Journal of Clinical Oncology|2020Cited by 292